In platinum–taxane resistant epithelial ovarian cancer (EOC), we aimed to determine the effectiveness.
Between 2004 and 2013, patients afflicted with platinum–taxane resistant EOC and who were administered a 30-minute i.v. infusion of single-agent gemcitabine at a dose of 1,250 mg/m2 on the 1st, 8th and 15th days, every 28 days, were examined retrospectively.
Twenty-six patients with platinum–taxane resistant EOC were included in the study. The overall survival (OS) was 48 months. The median survival after becoming platinum–taxane resistant was 16 months for the study population. Median time to progression (TTP) and median survival after becoming platinum–taxane resistant for patients who received second-line treatment were 3.3 months and 16 months, respectively; for patients who received third-line treatment with gemcitabine, these were 3.7 months and 19 months, respectively. Administration of gemcitabine as second- and third-line chemotherapy in platinum–taxane resistant EOC, provides similar TTP and OS outcomes (p = 0.4, p = 0.9) with a similar response and toxicity rate.
Second- and third-line gemcitabine at a dose of 1,250 mg/m2 on days 1, 8 and 15 every 28 days as a 30-minute i.v. infusion in platinum–taxane resistant EOC is an effective treatment option with a tolerable and manageable toxicity.
Tumori 2015; 101(1): 36 - 40
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsHilmi Kodaz, Ilhan Hacibekiroglu, Esma Turkmen, Bulent Erdogan, Cagnur Elpen, Sernaz Uzunoglu, Irfan Cicin
- • Accepted on 27/05/2014
- • Available online on 06/02/2015
- • Published in print on 20/03/2015
This article is available as full text PDF.
- Kodaz, Hilmi [PubMed] [Google Scholar] 1, * Corresponding Author (email@example.com)
- Hacibekiroglu, Ilhan [PubMed] [Google Scholar] 1
- Turkmen, Esma [PubMed] [Google Scholar] 1
- Erdogan, Bulent [PubMed] [Google Scholar] 1
- Elpen, Cagnur [PubMed] [Google Scholar] 2
- Uzunoglu, Sernaz [PubMed] [Google Scholar] 1
- Cicin, Irfan [PubMed] [Google Scholar] 1
Department of Medical Oncology, Faculty of Medicine, Trakya University Edirne - Turkey
Department of Public Health Institution of Edirne, Edirne - Turkey